Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Molecular Testing in Gliomas: What is Necessary in Routine Clinical Practice?

Current oncology reports - 1 Nov 2024

Alnahhas Iyad

Abstract excerpt

PURPOSE OF REVIEW: A number of molecular characteristics are essential for accurate diagnosis and prognostication in glioma. RECENT FINDINGS: The 2021 WHO classification of brain tumors and recent Food and Drug Administration (FDA) pathology agnostic drug approvals highlight the importance of molecular testing in the management of glioma. For diffuse gliomas, it is important to identify IDH mutations, given the...

Topics

Join the communities discussing this publication.

DNA Methylation
Biomarkers, Tumor
Brain Neoplasms
DNA Modification Methylases
DNA Repair Enzymes
Glioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Isocitrate Dehydrogenase

Tumor Suppressor Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 39361075
DOI: 10.1007/s11912-024-01602-w
PMCID: PMC11579106

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular Testing in Gliomas: What is Necessary in Routine Clinical Practice?PMID 39361075Read ↗

Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline.Semantic proximity Read ↗

Glioma 2021 WHO Classification: The Superiority of NGS Over IHC in Routine Diagnostics.Semantic proximity Read ↗

Diagnostic utility of genetic alterations in distinguishing IDH-wildtype glioblastoma from lower-grade gliomas: Insight from next-generation sequencing analysis of 479 cases.Semantic proximity Read ↗

Clinical impact of molecular profiling in rare brain tumors.Semantic proximity Read ↗

Clinical Laboratory Testing Practices in Diffuse Gliomas Prior to Publication of 2021 World Health Organization Classification of Central Nervous System Tumors.Semantic proximity Read ↗

IDH mutation testing in gliomas-where do we draw the line?Semantic proximity Read ↗

Development of a rapid and comprehensive genomic profiling test supporting diagnosis and research for gliomas.Semantic proximity Read ↗

Molecular Neuropathology in Practice: Clinical Profiling and Integrative Analysis of Molecular Alterations in GlioblastomaSemantic proximity Read ↗

Molecular Testing of Brain TumorSemantic proximity Read ↗

Clinical actionability in gliomas revealed by real-world next-generation sequencing: a multicentric studySemantic proximity Read ↗

Molecular profiling of CNS tumors for the treatment and management of disease.Semantic proximity Read ↗

IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.